CVR Meeting impact













you act like this drug is a dog! It’s doing well considering the patient type. You must be lack luster salesperson

Kerendia performance driven by non sustainable factors like FTP, zero dollar copay cards and giving credit to deep discounted Medicaid NRX. Take out California and NYC and I think any clear minded person would agree the performance is not good.